Sumitomo Dainippon Pharma confirmed its takeover talks with Australian stem cell firm Cynata Therapeutics in a brief statement on July 19, with the Japanese company ready to put up some 15 billion yen for the deal, if materialized. The statement…
To read the full story
Related Article
- Sumitomo Dainippon Drops Bid to Buy Cynata
October 18, 2019
- Fujifilm Grabs Rights to Cynata’s Cell Therapy for GVHD
September 18, 2019
- Fujifilm Gets 10%-plus Stake in Australian Cell Therapy Startup
September 6, 2016
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





